ATC Group: A02BA01 Cimetidine

Anatomical Therapeutic Chemical Classification System

Hierarchical position in ATC classification

Level
Code
Title
1
Alimentary tract and metabolism
2
Drugs for acid related disorders
3
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
4
H2-receptor antagonists
5
A02BA01
Cimetidine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route
Amount
ORAL - Oral
0.8 g
PAREN - Parenteral
0.8 g

Active ingredients

Active Ingredient
Description

Cimetidine is a histamine H2-receptor antagonist which rapidly inhibits both basal and stimulated gastric secretion of acid and reduces pepsin output. It is a reversible, competitive antagonist, and is used as an anti-ulcer drug.

Medicines in this ATC group

Drug
Countries

South Africa

South Africa

Hong Kong

Hong Kong

Hong Kong

Hong Kong

Hong Kong

Hong Kong

Hong Kong

Hong Kong

Ecuador

South Africa

Hong Kong

Hong Kong

Hong Kong

Hong Kong

South Africa

Hong Kong

South Africa

South Africa

Hong Kong

Singapore

South Africa

South Africa

Hong Kong

Hong Kong

Tunisia

South Africa

Hong Kong Singapore

Hong Kong

Hong Kong

Hong Kong

Hong Kong

Brazil South Africa United Kingdom

Hong Kong

Hong Kong

Hong Kong

Hong Kong

Hong Kong

South Africa

South Africa

Hong Kong

Hong Kong

Cyprus Hong Kong

South Africa

Hong Kong

Hong Kong

Tunisia

Hong Kong Singapore

Related product monographs

Title
Type
Country
Summary of Product Characteristics (SPC)
UK
Summary of Product Characteristics (SPC)
CY